About KaryoLogic
KaryoLogic is a company based in Durham (United States) founded in 2008 was acquired by Clean Cells in April 2025. KaryoLogic offers products and services including Human Stem Cell Karyotyping and Digital PCR, Human Non-Stem Cell Karyotyping, Non-Human Species Karyotyping, and Fluorescence In Situ Hybridization. KaryoLogic operates in a competitive market with competitors including Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Karyologic, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Clean Cells
(Apr 08, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KaryoLogic
KaryoLogic offers a comprehensive portfolio of products and services, including Human Stem Cell Karyotyping and Digital PCR, Human Non-Stem Cell Karyotyping, Non-Human Species Karyotyping, and Fluorescence In Situ Hybridization.
Analyzes chromosomes in human stem cells for research integrity
Performs chromosome analysis on human non-stem cells
Offers karyotyping for animal and other species
Detects specific DNA sequences in chromosomes
Funding Insights of KaryoLogic
Detailed funding history for KaryoLogic
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in KaryoLogic
KaryoLogic has secured backing from 1 investor. Prominent investors backing the company include Clean Cells.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Offers cell banking and virus banking services
|
Locked | Locked | Locked |
Investor details for KaryoLogic
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KaryoLogic
Investment portfolio details for KaryoLogic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KaryoLogic
Detailed financials for KaryoLogic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Karyologic Comparisons
Peer comparison for KaryoLogic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KaryoLogic
KaryoLogic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of drug discovery and preclinical development services
|
|
| Locked | Locked | Locked |
Provider of laboratory tests for physicians
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Provider of clinical research, development, and commercialization services for life sciences
|
|
| Locked | Locked | Locked |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare.
|
|
| Locked | Locked | Locked |
Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices
|
Detailed competitors of KaryoLogic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Karyologic
Complete news archive for KaryoLogic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KaryoLogic
KaryoLogic was founded in 2008.
KaryoLogic is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
KaryoLogic offers karyotyping services for human, mouse, and rare species, stem cell and cancer cell lines, as well as digital PCR services for human stem cells. They accept cell samples shipped from around the globe to their North Carolina USA location for high quality karyotyping services. KaryoLogic has also partnered with other biotech companies to improve their services.
KaryoLogic's top competitors include LabCorp, Charles River Laboratories and Cytel.
KaryoLogic offers Human Stem Cell Karyotyping and Digital PCR, Human Non-Stem Cell Karyotyping, Non-Human Species Karyotyping, and Fluorescence In Situ Hybridization.
KaryoLogic has 1 investor. Key investors include Clean Cells.